Rheumatology Advance Access originally published online on February 23, 2008
Rheumatology 2008 47(4):548-549; doi:10.1093/rheumatology/ken026
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
LETTERS TO THE EDITOR |
Risk of cancer in Turkish patients after treatment with TNF antagonists
GATA, Romatoloji BD, 06118 Etlik, Ankara, Turkey
Correspondence to: S. PAY, GATA Romatoloji BD, 06118 Etlik, Ankara, Turkey. E-mail: salihp@yahoo.com
| The first 10% of the full text of this article appears below. |
SIR, There is conflicting evidence whether anti-TNF therapy offers an increased cancer risk in rheumatological disorders. In this study, we aimed to collect pilot data on a possible association between anti-TNF agent use and development of neoplasms among Turkish patients with various rheumatological conditions.
We conducted a nationwide survey pooling reported cases from 26 different rheumatology centers in Turkey. A total of 2199 patients (1247 females, 952 males, mean age: 41.8 ± 13.9 yrs) were reported. Among those patients, 943 had AS (1027.16 patient-years) (mean age: 37.3 ± 10.9 yrs), 931 RA (1145.14 patient-years) (mean age: 49.1 ± 12.7 yrs), 132 PsA (mean age: 43.6 ± 12.5 yrs), 127